---
title: "Moderna Stock Edges Higher Tuesday: What's Happening?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296922818.md"
description: "Moderna (MRNA) shares rose in Tuesday premarket trading, up nearly 3%, driven by analyst upgrades and positive Phase 3 oncology data. Wolfe Research upgraded the stock following BofA's price target increase to $170. The bullish sentiment stems from a joint announcement with Merck that their personalized mRNA cancer vaccine met primary endpoints for recurrence-free survival in high-risk melanoma patients, boosting confidence in Moderna's pipeline expansion into oncology."
datetime: "2026-08-25T13:18:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296922818.md)
  - [en](https://longbridge.com/en/news/296922818.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296922818.md)
generator: "portal-rs"
---

# Moderna Stock Edges Higher Tuesday: What's Happening?

Shares of **Moderna Inc**. (NASDAQ:MRNA) are trading higher Tuesday morning, as Wall Street analysts upgrade their ratings following landmark Phase 3 oncology data.

Wolfe Research upgraded Moderna Tuesday morning, following a similar move by BofA Securities last week to raise its price target to $170.

-   Moderna stock is showing upward bias. What should traders watch with MRNA?

**Phase 3 Melanoma Trial Meets Primary Endpoints With Partner Merck**

Underpinning the bullish sentiment is a major clinical milestone announced on Aug. 19, alongside partner **Merck & Co Inc**. (NYSE:MRK).

The companies confirmed that their Phase 3 INTerpath-001 trial of intismeran autogene, a personalized mRNA cancer vaccine evaluated in combination with Keytruda, met its primary endpoint of recurrence-free survival and secondary endpoint of distant metastasis-free survival in patients with resected high-risk melanoma. 

The positive data has boosted investor confidence in Moderna’s late-stage pipeline, solidifying its expansion beyond infectious disease vaccines into high-value oncology applications.

## MRNA Stock Edges Higher Tuesday

**MRNA Price Action:** Moderna shares were up 2.97% at $143.01 during premarket trading on Tuesday, according to Benzinga Pro data.

 **Read Also: Court Rejects Merck’s Challenge to Medicare Drug Price Negotiation Program** 

*Image: Shutterstock*

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock](https://longbridge.com/en/news/297959605.md)
- [Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It](https://longbridge.com/en/news/298134130.md)
- [Moderna Chief Legal Officer Shannon Thyme Klinger disposes of USD 485,271.45 in common shares](https://longbridge.com/en/news/297958452.md)
- [Moderna Raises $3.0 Billion via 2032 Zero-Coupon Converts; Adds Capped Calls to Limit Dilution](https://longbridge.com/en/news/297697426.md)
- [Medicus Pharma pivots to precision oncology, prioritizing CD228V melanoma proof-of-concept study](https://longbridge.com/en/news/298310825.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**